Literature DB >> 22519435

Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma.

Shuhei Komatsu1, Daisuke Ichikawa, Hiroki Takeshita, Hirotaka Konishi, Hiroaki Nagata, Shoji Hirajima, Tsutomu Kawaguchi, Tomohiro Arita, Atsushi Shiozaki, Hitoshi Fujiwara, Kazuma Okamoto, Eigo Otsuji.   

Abstract

BACKGROUND: miR-21 and miR-375 are reported to be highly and poorly expressed in esophageal squamous cell carcinoma (ESCC) tissues, respectively. Recently, we demonstrated that circulating miR-21 and miR-375 were stably detectable in plasma and reflected tumor dynamics as a tumor marker for ESCC. We hypothesized that these plasma miRNA concentrations contributed to prognostic markers in patients with ESCC.
METHODS: Between 2008 and 2010, 50 preoperative plasma samples were collected from consecutive patients with ESCC, who underwent curative esophagectomy in our hospital. We examined the association between plasma miRNA concentrations and prognosis retrospectively.
RESULTS: i) The postoperative cause-specific survival rate of patients with high plasma miR-21 concentration tended to be poorer than low group (3-yr survival rate: 53.4 and 81.5%, p = 0.1038), while that of high plasma miR-375 group was better than low group (3-yr survival rate: 100 and 65.2%). ii) Patients with high miR-21 and low miR-375 concentrations in plasma had significantly poorer prognosis than other patients (3-yr survival rate: 48.4 and 83.1%, p = 0.039). Multivariate analysis revealed that the presence of high miR-21 and low miR-375 concentrations in plasma was an independent prognostic factor (p = 0.029, hazard ratio 3.8 (1.14-12.5)).
CONCLUSION: Circulating miR-21 and miR-375 could be reliable prognostic markers for ESCC. These plasma markers might facilitate clinical decision-making to select prospective candidates, which need meticulous follow-up for early detection of recurrences and additional treatments such as neo-adjuvant chemotherapy and postoperative chemotherapy in ESCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22519435     DOI: 10.1517/14712598.2012.681373

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  44 in total

Review 1.  The role of microRNA in esophageal squamous cell carcinoma.

Authors:  Kazuto Harada; Yoshifumi Baba; Takatsugu Ishimoto; Hironobu Shigaki; Keisuke Kosumi; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  J Gastroenterol       Date:  2016-01-21       Impact factor: 7.527

2.  Prognostic value of circulating microRNA-21 in digestive system cancers: a meta-analysis.

Authors:  Ting-Ting Ye; Yin-Long Yang; Xin-Ying Liu; Qian-Qing Ji; Yi-Fei Pan; You-Qun Xiang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

3.  The microRNA-375 as a potentially promising biomarker to predict the prognosis of patients with head and neck or esophageal squamous cell carcinoma: a meta-analysis.

Authors:  Peng Wang; LiangLiang Xu; Lian Li; ShengSheng Ren; JianWei Tang; Ming Zhang; MingQing Xu
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-12       Impact factor: 2.503

4.  MicroRNA-375 Suppresses Extracellular Matrix Degradation and Invadopodial Activity in Head and Neck Squamous Cell Carcinoma.

Authors:  Lizandra Jimenez; Ved P Sharma; John Condeelis; Thomas Harris; Thomas J Ow; Michael B Prystowsky; Geoffrey Childs; Jeffrey E Segall
Journal:  Arch Pathol Lab Med       Date:  2015-07-14       Impact factor: 5.534

5.  Circulating plasma microRNAs in the detection of esophageal squamous cell carcinoma.

Authors:  Lu Zhang; Bing Dong; Pengfei Ren; Hua Ye; Jianxiang Shi; Jiejie Qin; Kaijuan Wang; Peng Wang; Jianying Zhang
Journal:  Oncol Lett       Date:  2018-06-20       Impact factor: 2.967

Review 6.  Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma.

Authors:  Yasushi Toh; Akinori Egashira; Manabu Yamamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-03-26

7.  Circulating miRNA is a novel marker for head and neck squamous cell carcinoma.

Authors:  Cheng-Ming Hsu; Pai-Mei Lin; Yu-Ming Wang; Zong-Jyun Chen; Sheng-Fung Lin; Ming-Yu Yang
Journal:  Tumour Biol       Date:  2012-07-19

8.  Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.

Authors:  Xiaoyi Huang; Tiezheng Yuan; Meihua Liang; Meijun Du; Shu Xia; Rachel Dittmar; Dian Wang; William See; Brian A Costello; Fernando Quevedo; Winston Tan; Debashis Nandy; Graham H Bevan; Sherri Longenbach; Zhifu Sun; Yan Lu; Tao Wang; Stephen N Thibodeau; Lisa Boardman; Manish Kohli; Liang Wang
Journal:  Eur Urol       Date:  2014-08-14       Impact factor: 20.096

Review 9.  Cell-free microRNAs in blood and other body fluids, as cancer biomarkers.

Authors:  Blanca Ortiz-Quintero
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

10.  An integrative bioinformatics analysis identified miR-375 as a candidate key regulator of malignant breast cancer.

Authors:  Jiaxuan Liu; Ping Wang; Ping Zhang; Xinyu Zhang; Hang Du; Qiang Liu; Bo Huang; Caiyun Qian; Shuhua Zhang; Weifeng Zhu; Xiaohong Yang; Yingqun Xiao; Zhuoqi Liu; Daya Luo
Journal:  J Appl Genet       Date:  2019-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.